Shares in Chimeric Therapeutics (CHM.AX) continue to drift higher at $0.07, up roughly 8% this week, as investors digest a two-month-old clinical milestone that remains the stock's sole catalyst. On 27 April 2026, Chimeric announced that its Phase 1B trial of its natural killer (NK) cell therapy achieved a 60% complete response rate in 25 patients with acute myeloid leukemia (AML) — an aggressive blood cancer. No new company news has emerged since, yet the stock is holding gains. Here is what matters:
A Strong Response Rate, but in a Tiny Trial A 60% complete response rate is a genuinely impressive number. The trial, run at MD Anderson Cancer Center, focuses on high-risk frontline AML patients who cannot tolerate intensive chemotherapy — a notoriously difficult-to-treat group. But 25 patients is a very small sample. The data will need to hold up in larger, later-stage trials before regulators or partners will commit, meaning years of additional work lie ahead.
A $3 Million Market Cap Puts Enormous Risk on Full Display
Chimeric's market capitalization sits at roughly $2.85 million with only about 53.9 million shares outstanding after a recent share consolidation — a reverse split — approved by shareholders on 17 April 2026 . The company reported just $5.76 million in cash as of its most recent filing. With EPS of -$0.01 and no meaningful revenue , the math is stark: burn through your cash before proving the drug works, and you need to raise money — diluting current shareholders — or find a partner willing to fund the next steps.
NK Cell Therapy Is a Crowded and Fast-Moving Field Chimeric is not the only company chasing NK-cell treatments. At least 11 named competitors are active in clinical NK development , including well-funded players like Nkarta and Fate Therapeutics. The global NK cell therapy market is projected to reach roughly $4.7 billion by 2034 , a potentially large prize — but Chimeric would need to survive clinical, regulatory, and financial hurdles to claim any share of it.
The Bottom Line for Shareholders
Chimeric's portfolio spans both CAR T-cell and NK cell therapies targeting blood cancers and solid tumors , giving it multiple shots on goal. Two core cell therapy assets are advancing through late Phase 1, with further dose-level updates expected soon . Those readouts will likely determine whether the stock can sustain its modest rebound or sink back toward its 52-week lows. Until then, this remains a high-conviction, high-risk bet on early-stage science.